focus -WSS

focus

author：entertainment 2025-09-28 06:46:12 Page View：8715

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Former New York Mayor de Blasio and wife announce separation, but not divorce
Next article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

explore

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

ALS groups 'won't be played again' by the FDA, drug sponsors

MattScozzariholdshisgirlfriendSabrinaParker'shandduringafriendshipceremonyinJacksonville,N.C.,inNove

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Arebiotech’sdogdaysover?What’saPIPE?AndwhatcanunseatWegovy?Wecoverallthatandmorethisweekon“TheReadou